Stories of Survival: Brian Galgay and Karen Kent

Article

This video features the compelling stories of EC survivors: Brian Galgay and Karen Kent.

This video was produced by The Esophageal Cancer Awareness Association. It features the compelling stories of EC survivors: Brian Galgay and Karen Kent.

Recent Videos
woman in front of a blue background with dark hair
Related Content
Simple white line illustration of a clipboard that says "FDA" at the top, with a checkmark symbol overlapping the clipboard

Oncology Drugs Approved by the FDA in January 2025

Darlene Dobkowski, MA
February 3rd 2025
Article

January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.

The Vitals

What New Cancer Drugs Were Approved in 2023?

Lindsay Fischer
January 1st 2024
Podcast

In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.

yellow background with a white outline indicating ovaries and other gynecological structures

Azenosertib Demonstrates Activity and Tolerability in Ovarian Cancer

Ashling Wahner
February 2nd 2025
Article

Azenosertib (ZN-c3) demonstrated activity as a single agent in heavily pretreated patients with platinum-resistant, cyclin E1-positive ovarian cancer.

The Vitals

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

Lindsay Fischer
December 14th 2023
Podcast

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Close-up blue visual of an ovary with a tumor highlighted in orange

Olaparib Increases OS in Patients with Germline/Somatic BRCA+ Relapsed Ovarian Cancer

Ashley Chan
January 31st 2025
Article

Patients with relapsed ovarian cancer who had germline or somatic BRCA mutations saw greater OS with olaparib, according to data from the LIGHT trial.

Blue diagram of a person with gastrointestinal tract highlighted in orange

Sintilimab Plus Chemoradiotherapy Improves pCR Rate in Resectable, Locally Advanced ESCC

Chris Ryan
January 31st 2025
Article

Sintilimab with neoadjuvant chemoradiotherapy enhanced pCR rates in resectable, locally advanced esophageal squamous cell carcinoma.